NRP1 and COVID-19: By mapping ambroxol’s potential target to Coronavirus disease—COVID-19 pathway in KEGG, we found that ambroxol might interact with the SARS-CoV-2 cell entry receptor, NRP-1, on cellular surface (Figure 2A).